Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Cutaneous and pulmonary sarcoidosis following treatment of multiple sclerosis with interferon-beta-1b: a case report.
Double blind placebo-controlled Phase I/II clinical trial of idebenone in patients with primary progressive multiple sclerosis (IPPoMS)
Multiple sclerosis.
The Many Facets of Cell Injury: Angiogenesis to Autophagy.
Brain gadolinium enhancement along the ventricular and leptomeningeal regions in patients with aquaporin-4 antibodies in cerebral spinal fluid.
LINGO-1 is a component of the Nogo-66 receptor/p75 signaling complex.
Genetic analysis of the aquaporin-4 gene for anti-AQP4 antibody-positive neuromyelitis optica in a Japanese population.
Treatment of multiple sclerosis with anti-CD20 antibodies.
Predictors of quality of life among multiple sclerosis patients: a comprehensive analysis.
A comparative study of experimental mouse models of central nervous system demyelination.
Lenalidomide, Dexamethasone and MEDI-551 in Untreated Multiple Myeloma
The epidemiology of multiple sclerosis in Latin America and the Caribbean: a systematic review.
Natalizumab: alpha 4-integrin antagonist selective adhesion molecule inhibitors for MS.
Ultrasound aspects in therapy-naive CIDP compared to long-term treated CIDP.
Tumefactive multiple sclerosis lesions under fingolimod treatment.
The OSCAR-IB Consensus Criteria for Retinal OCT Quality Assessment.
Retrospective US database analysis of persistence with glatiramer acetate vs. available disease-modifying therapies for multiple sclerosis: 2001-2010.
Longitudinal assessment of immuno-metabolic parameters in multiple sclerosis patients during treatment with glatiramer acetate.
Meralgia paresthetica after subcutaneous injection of glatiramer acetate.
Severe anemia in a patient with multiple sclerosis treated with natalizumab.
T cells become licensed in the lung to enter the central nervous system.
Galectin-1 for neuroprotection?
Efficacy and safety of interferon beta-1b sc in older RRMS patients--a posthoc analysis of the BEYOND study.
Impact of glatiramer acetate on paraclinical markers of neuroprotection in multiple sclerosis: A prospective observational clinical trial.
Transcriptional response to interferon beta-1a treatment in patients with secondary progressive multiple sclerosis.

Pages